

Orthocell's International Commercial Expansion of Remplir™ Continues with Appointment of Exclusive Distributor to Commence Sales in Singapore

- Device Technologies Asia has been appointed as exclusive distributor in Singapore for Orthocell's market leading nerve repair device Remplir™
- The agreement extends a very successful distribution partnership with Device Technologies which distributes Remplir in Australia and New Zealand, where sales have grown rapidly since launch
- Device Technologies Asia is well positioned to replicate this success with a dedicated sales team in Singapore and established relationships with leading plastic reconstructive and orthopaedic surgeons
- Market launch preparations are already well underway, and the Company is expecting first sales of Remplir in Singapore in Q1 CY25
- The rapid progression from Remplir's recent regulatory approval in Singapore to signing the distribution agreement with Device Technologies Asia demonstrates the Company's commitment to rapid global expansion and revenue generation in new markets
- Singapore is a strategic jurisdiction, both as a destination for sophisticated medical treatments in the region and as a regulatory gateway to other substantial ASEAN markets, in a global nerve repair market estimated to exceed US\$3.5 billion¹.
- Orthocell has a strong balance sheet with circa \$35 million in cash to drive the Singapore market launch, along with accelerating its regulatory program into other jurisdictions, including the key US market, Canada, UK, Europe and other ASEAN markets
- Orthocell remains on schedule to release top-line results from its Remplir US market authorisation study and submit its Remplir US 510(K) application in Q4 CY24, with progression into US FDA approval expected late in Q1 CY25.

Perth, Australia; 27 November 2024: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce it has appointed Device Technologies Asia ("DVT Asia") as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore. Remplir has rapidly growing sales in the Australian and New Zealand markets, with an increasing number of surgeons using and endorsing its unique repair qualities. Singapore represents the first major international market launch outside the existing markets of Australia and New Zealand. Orthocell is well positioned to achieve first sales in this strategic jurisdiction in Q1 CY25. DVT Asia is the ideal distribution partner, having already established relationships with target customers including leading plastic reconstructive and orthopaedic surgeons at high quality surgical centres.

Orthocell CEO and MD, Paul Anderson, said: "Device Technologies Asia is a leading supplier of innovative medical solutions to hospitals and healthcare professionals throughout Singapore and South East Asia. We are delighted to extend our very successful distribution partnership with Device Technologies in Australia and New Zealand into Singapore. They have a proven track record in successfully driving the market entry of high-quality products with specialist capabilities and resources, and in the marketing, promotion and distribution of Remplir™. We are very much looking forward to working with DVT Asia to establish Remplir as the highest

¹ Addressable markets include AUS, USA, EU/UK, SGP, CAN, BRZ, JAP & THA. Referenced papers were used to estimate procedures per annum. Papers used included both US and OUS databases and studies.

quality nerve repair device in Singapore. We expect revenue growth and surgeon adoption of Remplir to accelerate from market launch in Q1 CY25.”

The rapid progression from Remplir’s recent regulatory approval from the Health Sciences Authority (HSA) in Singapore to signing the distribution agreement with DVT Asia is further validation of the Company’s commitment to global expansion and revenue generation in new markets. DVT Asia will market and distribute Remplir for use in the surgical repair of peripheral nerves across Singapore, undertaking medical education, targeted promotion activities and initiating sales, as well as expanding the network of referring plastic and orthopaedic surgeons. The exclusive distribution agreement has an initial term of five years and enables Orthocell access to this strategic market, with a growing uptake of Australian Made, high-quality healthcare products.

Commenting on the Agreements, Managing Director of Device Technologies Asia, Nat McLay, said: *“I am extremely excited to partner with Orthocell to bring their Australian Made range of peripheral nerve repair devices to plastic and orthopaedic surgeons in Singapore. At Device Technologies Asia we believe in investing in innovative technologies as part of a holistic portfolio that provides value to our customers and benefits their patients. We look forward to working with the team at Orthocell to improve patient outcomes across the plastic reconstructive and orthopaedic industry.”*

With circa \$35 million in cash and no debt, Orthocell is well-positioned to successfully launch Remplir in Singapore and other key markets including United States, South East Asia, Canada and the EU/UK. Importantly, the Company remains on schedule to release top-line results from its Remplir US market authorisation study and submit its Remplir US 510(K) application in Q4 CY24, with progression into US FDA approval and sales soon thereafter.

About Device Technologies Asia

Since 1992, DVT Asia has remained committed to providing healthcare professionals with access to innovative, high-quality medical devices and solutions from around the world. The DVT Asia’s vision is to enable superior health outcomes by connecting healthcare professionals with the finest medical technologies and supplies in the market.

The Device Technologies Group continues to grow, with over 200+ trusted brands and 1,000 highly skilled staff across Australia, New Zealand and Asia. All products distributed by Device Technologies are compliant with quality and regulatory requirements, with in-servicing, education and ongoing clinical and technical support provided as part of the trusted partnership between Device Technologies’ staff and healthcare professionals. For more information, visit devicetechnologies.asia.

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

ACN 118 879 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.